⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7227904 | 0.96 | — | — | |
| SCHEMBL3346553 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL17080481 | 0.67 | — | — | |
| SCHEMBL7227907 | 0.62 | — | — | |
| SCHEMBL28348 | 0.61 | — | — | |
| SCHEMBL17996894 | 0.61 | — | — | |
| SCHEMBL8173455 | 0.61 | — | — | |
| SCHEMBL402036 | 0.61 | — | — | |
| SCHEMBL21458008 | 0.60 | — | — | |
| SCHEMBL5193000 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109071427-B | Novel prostaglandin derivative | ＡＧＣ株式会社 | 2024-08-20 | — | — | CN | disclosed |
| EP-3456710-B1 | NOVEL PROSTAGLANDIN DERIVATIVE | AGC INC (JP) | 2021-06-30 | — | — | EP | disclosed |
| CN-107001295-B | Isoxazole hydroxamic acid compounds as LpxC inhibitors | 诺华股份有限公司 | 2021-02-02 | — | — | CN | disclosed |
| EP-3468957-B1 | CRYSTALLINE FORM OF (R)-4-(5-(CYCLOPROPYLETHYNYL)ISOXAZOL-3-YL)-N-HYDROXY-2-METHYL-2-(METHYLSULFONYL)BUTANAMIDE AS AN ANTIBACTERIAL AGENT | NOVARTIS AG (CH) | 2020-08-26 | — | — | EP | disclosed |
| US-10494338-B2 | Prostaglandin derivative | AGC Inc. (JP) | 2019-12-03 | — | — | US | disclosed |
| EP-3233843-B1 | ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LPXC INHIBITORS | NOVARTIS AG (CH) | 2019-10-16 | — | — | EP | disclosed |
| US-20190135743-A1 | NOVEL PROSTAGLANDIN DERIVATIVE | AGC Inc. (JP) | 2019-05-09 | — | — | US | disclosed |
| EP-3468957-A1 | CRYSTALLINE FORM OF (R)-4-(5-(CYCLOPROPYLETHYNYL)ISOXAZOL-3-YL)-N-HYDROXY-2-METHYL-2-(METHYLSULFONYL)BUTANAMIDE AS AN ANTIBACTERIAL AGENT | NOVARTIS AG (CH) | 2019-04-17 | — | — | EP | disclosed |
| EP-3456710-A1 | NOVEL PROSTAGLANDIN DERIVATIVE | AGC INC. (JP) | 2019-03-20 | — | — | EP | disclosed |
| US-10071973-B2 | Crystalline isoxazole hydroxamic acid compounds | NOVARTIS AG (CH) | 2018-09-11 | — | — | US | disclosed |
| US-20170355684-A1 | CRYSTALLINE ISOXAZOLE HYDROXAMIC ACID COMPOUNDS | NOVARTIS PHARMA AG (CH) | 2017-12-14 | — | — | US | disclosed |
| US-9815804-B2 | Isoxazole hydroxamic acid compounds as LpxC inhibitors | NOVARTIS AG (CH) | 2017-11-14 | — | — | US | disclosed |
| EP-3233843-A1 | ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LPXC INHIBITORS | Novartis AG (CH) | 2017-10-25 | — | — | EP | disclosed |
| US-20170088525-A1 | ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LpxC INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2017-03-30 | — | — | US | disclosed |
| WO-2017037039-A1 | ANTIBACTERIAL HETEROCYCLIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2017-03-09 | — | — | WO | disclosed |
| WO-2017036968-A1 | ANTIBACTERIAL ANNULATED PYRROLIDIN-2-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2017-03-09 | — | — | WO | disclosed |
| WO-2017037221-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE ANTIBACTERIAL COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2017-03-09 | — | — | WO | disclosed |
| US-9549916-B2 | Isoxazole hydroxamic acid compounds as LpxC inhibitors | NOVARTIS AG (CH) | 2017-01-24 | — | — | US | disclosed |
| WO-2016097995-A1 | ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LPXC INHIBITORS | NOVARTIS AG (CH) | 2016-06-23 | — | — | WO | disclosed |
| US-20160166548-A1 | ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LpxC INHIBITORS | NOVARTIS AG (CH) | 2016-06-16 | — | — | US | disclosed |